Molecular characterization of 350 hepatocellular carcinomas identifies biomarker aberrations with potential novel therapeutic options


Celina Ang1, John T. Miura2, T. Clark Gamblin2, Joanne Xiu3, Sherri Z. Millis3, Zoran Gatalica3, Sandeep K. Reddy3,4, Nelson S. Yee5

Background: Effective treatment strategies for hepatocellular carcinoma (HCC) remain limited. Identification of additional therapies remains paramount as currently available agents have resulted in marginal improvements in overall survival or are not appropriate for this patient population.

Download Publication